iX Biopharma Ltd - Just a warm up

29 Nov 2021
  • iX Biopharma signs outlicensing agreement for its Wafermine drug worth more than S$300mn (excluding royalties) with Nasdaq-listed Seelos Therapeutics. Seelos provides the regulatory, clinical development and local USA market knowledge to register and commercialise Wafermine and other ketamine-related products.
  • Seelos will fund future development, manufacturing and commercialisation of Wafermine and related drugs. iX Biopharma will receive an upfront payment, development milestone, sales milestone and royalties.
  • iX Biopharma retains the ownership over the WaferiX sublingual drug delivery technology. Wafermine is one of a portfolio of other drugs that iX Biopharma is re-purposing using Waferix.  Our DCF (WACC 10%) TP is raised to S$0.355 (prev. S$0.335) as we incorporate a higher upfront fee of S$12.1mn and raise development income. Our BUY recommendation is maintained.

Event

  1. Entered into an exclusive licence agreement with Nasdaq-listed Seelos Therapeutics (SEEL SP, Non-Rated) for Wafermine and other sublingual ketamine wafer products. Seelos will have exclusive worldwide rights (excluding China).
  2. iX Biopharma will receive three forms of revenue: a) US$9mn upfront payment to be satisfied in cash and shares; b) US$239mn in development and product sales thresholds milestones; and c) double-digit percentage royalties on future net sales of any licensed products.
  3. Seelos will fund all future development, manufacturing and commercialisation of the licensed products.
  4. Wafermine and other sublingual ketamine wafer products will be used in the treatment of severe acute pain, the rare disorder called Complex Regional Pain Syndrome and depression.

 

Comment

  1. Who and why Seelos? We believe iX Biopharma worked with Seelos for four reasons:
  • Seelos has the clinical expertise to complete Wafermine’s phase 3 programme and regulatory ability to secure FDA approval. The management team of Seelos are industry veterans who combined have more than 20 new drug approvals in the field of central nervous systems (CNS) from the FDA. Pain and depression are CNS conditions.
  • Experience in developing ketamine as a drug and the desire to build a ketamine franchise. Seelos is currently developing an intranasal ketamine drug (called SLS-002) to treat suicidal depression which is in an advanced registration stage with the FDA. SLS-002 has obtained fast track designation from the USA. Seelos has 2 other clinical programmes that have also received orphan and fast track designation from the FDA.
  • Access to US market liquidity. Seelos was listed on Nasdaq in January 2019, giving it access to a deep pool of liquidity or funds focused on biotechnology on NASDAQ. Its current market cap is US$189mn with net cash of around US$77mn (prior to its recent $50mn fund raising). It has progressively raised more than US$150mn in funds in the last 12 months to fund its various clinical programmes.
  • Seelos is based in the USA, giving it good local US knowledge and market access to potential distributors.
  1. What are milestones and royalties? Development milestone fees are payable upon achievement of clinical and regulatory milestones such as commencement of clinical trials, submissions to the FDA, and obtaining marketing approval from the FDA and regulators in other countries. Sales milestones are paid when certain revenue thresholds are achieved from selling the product. Double-digit royalties are collected from any sales of the drug.
  2. What are the key timelines? Development milestone fees would be payable as early as upon the commencement of Phase 2 human clinical trial for depression (FY23e). Another payment is due after filing the pain indication with the FDA. It will take approximately 12 months to receive marketing approval from the FDA (FY25e) when another payment will be due. Once approved the major revenue streams will be through sales milestones and royalty from the sale of the drug (FY26e onwards). Due to the addressable markets for pain and depression, sales of the drugs when registered are expected to be sizeable. Royalty payments could be larger than the combined milestone payments and provide a strong recurring revenue stream to iX Biopharma.

 

 

Recommendation

The out-licensing agreement is a significant breakthrough for the company to monetise its Wafermine drug with a recurring revenue stream. It also frees up its resources to develop other exciting products in its pipeline which can then be monetised in the same manner. This is made possible as the company maintains ownership of its WaferiX platform technology. Maintain BUY with a higher DCF TP of S$0.355 (previously S$0.335) as we increase the upfront fee and raise the expected development income.

 

 

About the author

Paul Chew
Head of Research
Phillip Securities Research Pte Ltd

Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.

He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com